Home › Companies › BIOMARIN PHARMACEUTICAL INC. › 2024-2025

BIOMARIN PHARMACEUTICAL INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and BIOMARIN PHARMACEUTICAL INC.’s Form 8-K (Item 5.07 on EDGAR). Page generated 04 October 2026.

16Reported items
554Asset managers
7,322Fund votes
2025-05-20Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore BIOMARIN PHARMACEUTICAL INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by BIOMARIN PHARMACEUTICAL INC.

These tallies are BIOMARIN PHARMACEUTICAL INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

BIOMARIN PHARMACEUTICAL INC. — official shareholder meeting results, meeting held 2025-05-20
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Elizabeth M. Anderson	160,575,395	5,338,859	261,996	--	10,064,270	Majority: yes
Elect Director: Barbara W. Bodem	164,230,278	1,033,669	912,303	--	10,064,270	Majority: yes
Elect Director: Athena Countouriotis	163,915,734	1,656,229	604,287	--	10,064,270	Majority: yes
Elect Director: Willard Dere	163,380,097	2,536,182	259,971	--	10,064,270	Majority: yes
Elect Director: Mark J. Enyedy	164,211,417	1,412,156	552,677	--	10,064,270	Majority: yes
Elect Director: Alexander Hardy	164,875,088	1,051,826	249,336	--	10,064,270	Majority: yes
Elect Director: Maykin Ho	164,039,826	1,878,694	257,730	--	10,064,270	Majority: yes
Elect Director: Robert J. Hombach	163,224,408	2,694,927	256,915	--	10,064,270	Majority: yes
Elect Director: Richard A. Meier	160,566,321	5,338,585	271,344	--	10,064,270	Majority: yes
Elect Director: Timothy P. Walbert	165,166,799	662,209	347,242	--	10,064,270	Majority: yes
Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The ratification of the selection of KPMG LLP as BioMarin's independent registered public accounting firm for the fiscal year ending December 31, 2025, as set forth in t	168,601,089	7,442,009	197,422	--	--	Passed
Proposal 3: Advisory Vote on the Compensation of Named Executive Officers The advisory (non-binding) vote to approve the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement, received the following votes:	155,351,652	10,227,321	597,277	--	10,064,270	Passed
Proposal 4: Approval of an Amendment to the 2017 Equity Incentive Plan The approval of the Plan Amendment received the following votes:	157,280,864	7,747,768	1,147,618	--	10,064,270	Passed

Source: BIOMARIN PHARMACEUTICAL INC., Form 8-K — read the filing on EDGAR.

How asset managers voted at the BIOMARIN PHARMACEUTICAL INC. 2024-2025 meeting

Each item below shows how the 554 asset managers that disclosed a BIOMARIN PHARMACEUTICAL INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of BIOMARIN PHARMACEUTICAL INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.

SECTION 14A SAY-ON-PAY VOTESCompany result: Passed

Meeting held 2025-05-20.

Combines 13 wordings of this item as funds reported it.

94% Passed · of votes cast

FOR 94%

FOR: 155,351,652AGAINST: 10,227,321

BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Proposal 3: Advisory Vote on the Compensation of Named Executive Officers The advisory (non-binding) vote to approve the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement, received ”): 155,351,652 for, 10,227,321 against — passed, per its Form 8-K (Item 5.07). Of all 191,755,802 outstanding shares: 81% for, 5% against (86% of the company cast a for/against vote).

The 545 asset managers below cast 96% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

FOR 95%

FOR: 95.4%AGAINST: 4.3%ABSTAIN: 0.3%NOT VOTED: 0.0%

Largest asset managers voting on “To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in t” at BIOMARIN PHARMACEUTICAL INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	32,909,234	2,444	For
Dodge & Cox	25,698,158	0	For
BlackRock	21,516,532	16,657	For
PRIMECAP MANAGEMENT CO/CA/	17,067,608	0	For
State Street	10,847,657	76,489	For
VIKING GLOBAL INVESTORS LP	10,588,163	0	For
Capital Research Global Investors	9,147,555	0	For
Capital Group	8,669,173	0	For
Fidelity	3,859,536	0	For
GEODE CAPITAL MANAGEMENT, LLC	3,364,050	0	For
Charles Schwab	3,125,785	0	For
PRIMECAP Odyssey Funds	2,994,376	0	For
Columbia Threadneedle	2,850,469	0	For
AQR	1,564,636	0	For
JPMorgan	1,549,185	0	For
Northern Trust	1,515,660	16,832	For
Aberdeen	1,472,678	0	For
MELLON INVESTMENTS Corp	1,239,265	0	For
Palo Alto Investors LP	1,136,224	0	For
Soleus Capital Management, L.P.	1,089,304	0	For
AMERIPRISE FINANCIAL INC	1,062,067	0	For
Nuveen	0	1,041,152	Against
Goldman Sachs	1,020,702	0	For
DnB Asset Management AS	1,001,675	0	For
Dimensional	980,685	0	For

Showing the 25 largest of 545 asset managers. See all 545 in the interactive database.

2. To approve an amendment to the Company's 2017 Equity Incentive Plan, as amended.

COMPENSATIONCompany result: Passed

Meeting held 2025-05-20.

Combines 6 wordings of this item as funds reported it.

95% Passed · of votes cast

FOR 95%

FOR: 157,280,864AGAINST: 7,747,768

BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Proposal 4: Approval of an Amendment to the 2017 Equity Incentive Plan The approval of the Plan Amendment received the following votes:”): 157,280,864 for, 7,747,768 against — passed, per its Form 8-K (Item 5.07). Of all 191,755,802 outstanding shares: 82% for, 4% against (86% of the company cast a for/against vote).

The 137 asset managers below cast 99.1% of the shares they voted on this item FOR (88,031,165 for, 728,548 against).

FOR 99.1%

FOR: 88,031,165 (99.1%)AGAINST: 728,548 (0.8%)ABSTAIN: 66,717 (0.1%)

Largest asset managers voting on “To approve an amendment to the Company's 2017 Equity Incentive Plan, as amended.” at BIOMARIN PHARMACEUTICAL INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	32,152,236	1	For
BlackRock	12,596,604	0	For
Dodge & Cox	11,525,325	0	For
Capital Group	8,669,069	0	For
Fidelity	3,339,881	0	For
State Street	3,099,903	97	For
PRIMECAP Odyssey Funds	2,994,376	0	For
Columbia Threadneedle	2,813,621	0	For
Charles Schwab	1,505,451	0	For
TIAA	843,433	0	For
Aberdeen	721,531	0	For
First Trust	664,902	0	For
Capitol Series Trust	547,000	0	For
TOUCHSTONE STRATEGIC TRUST	517,507	0	For
Dimensional	488,764	0	For
JPMorgan	455,486	0	For
American Century	0	447,463	Against
Equitable	381,070	0	For
Jackson National	359,423	0	For
NEW ECONOMY FUND	289,881	0	For
AQR	236,403	0	For
Goldman Sachs	218,905	0	For
AIG/SunAmerica	212,188	0	For
John Hancock	191,443	0	For
Nationwide	162,879	0	For

Showing the 25 largest of 137 asset managers. See all 137 in the interactive database.

3. Election of Directors: Alexander Hardy

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-05-20.

Combines 4 wordings of this item as funds reported it.

99.3% Majority: yes · of votes cast

FOR 99.3%

FOR: 164,875,088AGAINST: 1,051,826

BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Alexander Hardy”): 164,875,088 for, 1,051,826 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 191,755,802 outstanding shares: 86% for, 0.6% against (87% of the company cast a for/against vote).

The 131 asset managers below cast 99.9% of the shares they voted on this item FOR (89,018,731 for, 6,597 against).

FOR 99.9%

FOR: 89,018,731 (99.9%)AGAINST: 6,597 (0.0%)ABSTAIN: 66,717 (0.1%)

Largest asset managers voting on “Election of Directors: Alexander Hardy” at BIOMARIN PHARMACEUTICAL INC., 2024-2025
Asset manager	For	Vote
Vanguard	32,152,237	For
BlackRock	12,596,604	For
Dodge & Cox	11,525,325	For
Capital Group	8,669,069	For
Fidelity	3,339,881	For
State Street	3,100,000	For
PRIMECAP Odyssey Funds	2,994,376	For
Columbia Threadneedle	2,813,621	For
Charles Schwab	1,505,451	For
TIAA	843,433	For
Aberdeen	721,531	For
First Trust	664,902	For
Capitol Series Trust	547,000	For
TOUCHSTONE STRATEGIC TRUST	517,507	For
Dimensional	488,764	For
JPMorgan	455,486	For
American Century	447,463	For
Equitable	381,070	For
Jackson National	359,423	For
NEW ECONOMY FUND	289,881	For
Empower	246,899	For
AQR	236,403	For
Goldman Sachs	218,905	For
AIG/SunAmerica	212,188	For
John Hancock	191,443	For

Showing the 25 largest of 131 asset managers. See all 131 in the interactive database.

4. Election of Directors: Athena Countouriotis

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-05-20.

Combines 4 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 163,915,734AGAINST: 1,656,229

BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Athena Countouriotis”): 163,915,734 for, 1,656,229 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 191,755,802 outstanding shares: 85% for, 0.9% against (86% of the company cast a for/against vote).

The 131 asset managers below cast 99.9% of the shares they voted on this item FOR (88,984,961 for, 40,367 against).

FOR 99.8%

FOR: 88,984,961 (99.9%)AGAINST: 40,367 (0.0%)ABSTAIN: 66,717 (0.1%)

Largest asset managers voting on “Election of Directors: Athena Countouriotis” at BIOMARIN PHARMACEUTICAL INC., 2024-2025
Asset manager	For	Vote
Vanguard	32,152,237	For
BlackRock	12,596,604	For
Dodge & Cox	11,525,325	For
Capital Group	8,669,069	For
Fidelity	3,339,881	For
State Street	3,100,000	For
PRIMECAP Odyssey Funds	2,994,376	For
Columbia Threadneedle	2,813,621	For
Charles Schwab	1,505,451	For
TIAA	843,433	For
Aberdeen	721,531	For
First Trust	664,902	For
Capitol Series Trust	547,000	For
TOUCHSTONE STRATEGIC TRUST	517,507	For
Dimensional	488,764	For
JPMorgan	455,486	For
American Century	447,463	For
Equitable	381,070	For
Jackson National	359,423	For
NEW ECONOMY FUND	289,881	For
Empower	246,899	For
AQR	236,403	For
Goldman Sachs	218,905	For
AIG/SunAmerica	212,188	For
John Hancock	191,443	For

Showing the 25 largest of 131 asset managers. See all 131 in the interactive database.

5. Election of Directors: Barbara W. Bodem

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-05-20.

Combines 4 wordings of this item as funds reported it.

99.3% Majority: yes · of votes cast

FOR 99.3%

FOR: 164,230,278AGAINST: 1,033,669

BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Barbara W. Bodem”): 164,230,278 for, 1,033,669 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 191,755,802 outstanding shares: 86% for, 0.6% against (86% of the company cast a for/against vote).

The 131 asset managers below cast 99.9% of the shares they voted on this item FOR (88,990,080 for, 35,248 against).

FOR 99.8%

FOR: 88,990,080 (99.9%)AGAINST: 35,248 (0.0%)ABSTAIN: 66,717 (0.1%)

Largest asset managers voting on “Election of Directors: Barbara W. Bodem” at BIOMARIN PHARMACEUTICAL INC., 2024-2025
Asset manager	For	Vote
Vanguard	32,152,237	For
BlackRock	12,596,604	For
Dodge & Cox	11,525,325	For
Capital Group	8,669,069	For
Fidelity	3,339,881	For
State Street	3,100,000	For
PRIMECAP Odyssey Funds	2,994,376	For
Columbia Threadneedle	2,813,621	For
Charles Schwab	1,505,451	For
TIAA	843,433	For
Aberdeen	721,531	For
First Trust	664,902	For
Capitol Series Trust	547,000	For
TOUCHSTONE STRATEGIC TRUST	517,507	For
Dimensional	488,764	For
JPMorgan	455,486	For
American Century	447,463	For
Equitable	381,070	For
Jackson National	359,423	For
NEW ECONOMY FUND	289,881	For
Empower	246,899	For
AQR	236,403	For
Goldman Sachs	218,905	For
AIG/SunAmerica	212,188	For
John Hancock	191,443	For

Showing the 25 largest of 131 asset managers. See all 131 in the interactive database.

6. Election of Directors: Elizabeth M. Anderson

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-05-20.

Combines 5 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 160,575,395AGAINST: 5,338,859

BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Elizabeth M. Anderson”): 160,575,395 for, 5,338,859 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 191,755,802 outstanding shares: 84% for, 3% against (87% of the company cast a for/against vote).

The 131 asset managers below cast 99.2% of the shares they voted on this item FOR (88,387,892 for, 637,436 against).

FOR 99.2%

FOR: 88,387,892 (99.2%)AGAINST: 637,436 (0.7%)ABSTAIN: 66,717 (0.1%)

Largest asset managers voting on “Election of Directors: Elizabeth M. Anderson” at BIOMARIN PHARMACEUTICAL INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	32,152,236	1	For
BlackRock	12,596,604	0	For
Dodge & Cox	11,525,325	0	For
Capital Group	8,669,069	0	For
Fidelity	3,339,881	0	For
State Street	3,100,000	0	For
PRIMECAP Odyssey Funds	2,994,376	0	For
Columbia Threadneedle	2,813,621	0	For
Charles Schwab	1,505,451	0	For
TIAA	843,433	0	For
Aberdeen	721,531	0	For
First Trust	664,902	0	For
Capitol Series Trust	547,000	0	For
TOUCHSTONE STRATEGIC TRUST	517,507	0	For
Dimensional	0	488,764	Against
JPMorgan	455,486	0	For
American Century	447,463	0	For
Equitable	381,070	0	For
Jackson National	353,795	5,628	For
NEW ECONOMY FUND	289,881	0	For
Empower	246,899	0	For
AQR	236,403	0	For
Goldman Sachs	218,905	0	For
AIG/SunAmerica	212,188	0	For
John Hancock	110,269	81,174	For

Showing the 25 largest of 131 asset managers. See all 131 in the interactive database.

7. Election of Directors: Mark J. Enyedy

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-05-20.

Combines 4 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%

FOR: 164,211,417AGAINST: 1,412,156

BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Mark J. Enyedy”): 164,211,417 for, 1,412,156 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 191,755,802 outstanding shares: 86% for, 0.8% against (86% of the company cast a for/against vote).

The 131 asset managers below cast 99.9% of the shares they voted on this item FOR (88,990,080 for, 35,248 against).

FOR 99.8%

FOR: 88,990,080 (99.9%)AGAINST: 35,248 (0.0%)ABSTAIN: 66,717 (0.1%)

Largest asset managers voting on “Election of Directors: Mark J. Enyedy” at BIOMARIN PHARMACEUTICAL INC., 2024-2025
Asset manager	For	Vote
Vanguard	32,152,237	For
BlackRock	12,596,604	For
Dodge & Cox	11,525,325	For
Capital Group	8,669,069	For
Fidelity	3,339,881	For
State Street	3,100,000	For
PRIMECAP Odyssey Funds	2,994,376	For
Columbia Threadneedle	2,813,621	For
Charles Schwab	1,505,451	For
TIAA	843,433	For
Aberdeen	721,531	For
First Trust	664,902	For
Capitol Series Trust	547,000	For
TOUCHSTONE STRATEGIC TRUST	517,507	For
Dimensional	488,764	For
JPMorgan	455,486	For
American Century	447,463	For
Equitable	381,070	For
Jackson National	359,423	For
NEW ECONOMY FUND	289,881	For
Empower	246,899	For
AQR	236,403	For
Goldman Sachs	218,905	For
AIG/SunAmerica	212,188	For
John Hancock	191,443	For

Showing the 25 largest of 131 asset managers. See all 131 in the interactive database.

8. Election of Directors: Maykin Ho

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-05-20.

Combines 4 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 164,039,826AGAINST: 1,878,694

BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Maykin Ho”): 164,039,826 for, 1,878,694 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 191,755,802 outstanding shares: 86% for, 1.0% against (87% of the company cast a for/against vote).

The 131 asset managers below cast 99.9% of the shares they voted on this item FOR (89,000,723 for, 24,605 against).

FOR 99.8%

FOR: 89,000,723 (99.9%)AGAINST: 24,605 (0.0%)ABSTAIN: 66,717 (0.1%)

Largest asset managers voting on “Election of Directors: Maykin Ho” at BIOMARIN PHARMACEUTICAL INC., 2024-2025
Asset manager	For	Vote
Vanguard	32,152,237	For
BlackRock	12,596,604	For
Dodge & Cox	11,525,325	For
Capital Group	8,669,069	For
Fidelity	3,339,881	For
State Street	3,100,000	For
PRIMECAP Odyssey Funds	2,994,376	For
Columbia Threadneedle	2,813,621	For
Charles Schwab	1,505,451	For
TIAA	843,433	For
Aberdeen	721,531	For
First Trust	664,902	For
Capitol Series Trust	547,000	For
TOUCHSTONE STRATEGIC TRUST	517,507	For
Dimensional	488,764	For
JPMorgan	455,486	For
American Century	447,463	For
Equitable	381,070	For
Jackson National	359,423	For
NEW ECONOMY FUND	289,881	For
Empower	246,899	For
AQR	236,403	For
Goldman Sachs	218,905	For
AIG/SunAmerica	212,188	For
John Hancock	191,443	For

Showing the 25 largest of 131 asset managers. See all 131 in the interactive database.

9. Election of Directors: Richard A. Meier

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-05-20.

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 160,566,321AGAINST: 5,338,585

BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Richard A. Meier”): 160,566,321 for, 5,338,585 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 191,755,802 outstanding shares: 84% for, 3% against (87% of the company cast a for/against vote).

The 131 asset managers below cast 99% of the shares they voted on this item FOR (88,008,625 for, 1,016,703 against).

FOR 99%

FOR: 88,008,625 (98.8%)AGAINST: 1,016,703 (1.1%)ABSTAIN: 66,717 (0.1%)

Largest asset managers voting on “Election of Directors: Richard A. Meier” at BIOMARIN PHARMACEUTICAL INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	32,150,431	1,806	For
BlackRock	12,596,604	0	For
Dodge & Cox	11,525,325	0	For
Capital Group	8,669,069	0	For
Fidelity	3,339,881	0	For
State Street	3,099,903	97	For
PRIMECAP Odyssey Funds	2,994,376	0	For
Columbia Threadneedle	2,813,621	0	For
Charles Schwab	1,505,451	0	For
TIAA	0	843,433	Against
Aberdeen	721,531	0	For
First Trust	664,902	0	For
Capitol Series Trust	547,000	0	For
TOUCHSTONE STRATEGIC TRUST	517,507	0	For
Dimensional	488,764	0	For
JPMorgan	455,486	0	For
American Century	447,463	0	For
Equitable	381,070	0	For
Jackson National	359,423	0	For
NEW ECONOMY FUND	289,881	0	For
Empower	246,899	0	For
AQR	236,403	0	For
Goldman Sachs	218,905	0	For
AIG/SunAmerica	212,188	0	For
John Hancock	191,443	0	For

Showing the 25 largest of 131 asset managers. See all 131 in the interactive database.

10. Election of Directors: Robert J. Hombach

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-05-20.

Combines 4 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 163,224,408AGAINST: 2,694,927

BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Robert J. Hombach”): 163,224,408 for, 2,694,927 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 191,755,802 outstanding shares: 85% for, 1% against (87% of the company cast a for/against vote).

The 131 asset managers below cast 99.9% of the shares they voted on this item FOR (88,981,620 for, 43,708 against).

FOR 99.8%

FOR: 88,981,620 (99.9%)AGAINST: 43,708 (0.0%)ABSTAIN: 66,717 (0.1%)

Largest asset managers voting on “Election of Directors: Robert J. Hombach” at BIOMARIN PHARMACEUTICAL INC., 2024-2025
Asset manager	For	Vote
Vanguard	32,152,237	For
BlackRock	12,596,604	For
Dodge & Cox	11,525,325	For
Capital Group	8,669,069	For
Fidelity	3,339,881	For
State Street	3,100,000	For
PRIMECAP Odyssey Funds	2,994,376	For
Columbia Threadneedle	2,813,621	For
Charles Schwab	1,505,451	For
TIAA	843,433	For
Aberdeen	721,531	For
First Trust	664,902	For
Capitol Series Trust	547,000	For
TOUCHSTONE STRATEGIC TRUST	517,507	For
Dimensional	488,764	For
JPMorgan	455,486	For
American Century	447,463	For
Equitable	381,070	For
Jackson National	359,423	For
NEW ECONOMY FUND	289,881	For
Empower	246,899	For
AQR	236,403	For
Goldman Sachs	218,905	For
AIG/SunAmerica	212,188	For
John Hancock	191,443	For

Showing the 25 largest of 131 asset managers. See all 131 in the interactive database.

11. Election of Directors: Timothy P. Walbert

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-05-20.

Combines 4 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%

FOR: 165,166,799AGAINST: 662,209

BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Timothy P. Walbert”): 165,166,799 for, 662,209 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 191,755,802 outstanding shares: 86% for, 0.4% against (86% of the company cast a for/against vote).

The 131 asset managers below cast 99.9% of the shares they voted on this item FOR (89,015,130 for, 10,198 against).

FOR 99.9%

FOR: 89,015,130 (99.9%)AGAINST: 10,198 (0.0%)ABSTAIN: 66,717 (0.1%)

Largest asset managers voting on “Election of Directors: Timothy P. Walbert” at BIOMARIN PHARMACEUTICAL INC., 2024-2025
Asset manager	For	Vote
Vanguard	32,152,237	For
BlackRock	12,596,604	For
Dodge & Cox	11,525,325	For
Capital Group	8,669,069	For
Fidelity	3,339,881	For
State Street	3,100,000	For
PRIMECAP Odyssey Funds	2,994,376	For
Columbia Threadneedle	2,813,621	For
Charles Schwab	1,505,451	For
TIAA	843,433	For
Aberdeen	721,531	For
First Trust	664,902	For
Capitol Series Trust	547,000	For
TOUCHSTONE STRATEGIC TRUST	517,507	For
Dimensional	488,764	For
JPMorgan	455,486	For
American Century	447,463	For
Equitable	381,070	For
Jackson National	359,423	For
NEW ECONOMY FUND	289,881	For
Empower	246,899	For
AQR	236,403	For
Goldman Sachs	218,905	For
AIG/SunAmerica	212,188	For
John Hancock	191,443	For

Showing the 25 largest of 131 asset managers. See all 131 in the interactive database.

12. Election of Directors: Willard Dere

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-05-20.

Combines 4 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 163,380,097AGAINST: 2,536,182

BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Willard Dere”): 163,380,097 for, 2,536,182 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 191,755,802 outstanding shares: 85% for, 1% against (87% of the company cast a for/against vote).

The 131 asset managers below cast 99.9% of the shares they voted on this item FOR (88,981,620 for, 43,708 against).

FOR 99.8%

FOR: 88,981,620 (99.9%)AGAINST: 43,708 (0.0%)ABSTAIN: 66,717 (0.1%)

Largest asset managers voting on “Election of Directors: Willard Dere” at BIOMARIN PHARMACEUTICAL INC., 2024-2025
Asset manager	For	Vote
Vanguard	32,152,237	For
BlackRock	12,596,604	For
Dodge & Cox	11,525,325	For
Capital Group	8,669,069	For
Fidelity	3,339,881	For
State Street	3,100,000	For
PRIMECAP Odyssey Funds	2,994,376	For
Columbia Threadneedle	2,813,621	For
Charles Schwab	1,505,451	For
TIAA	843,433	For
Aberdeen	721,531	For
First Trust	664,902	For
Capitol Series Trust	547,000	For
TOUCHSTONE STRATEGIC TRUST	517,507	For
Dimensional	488,764	For
JPMorgan	455,486	For
American Century	447,463	For
Equitable	381,070	For
Jackson National	359,423	For
NEW ECONOMY FUND	289,881	For
Empower	246,899	For
AQR	236,403	For
Goldman Sachs	218,905	For
AIG/SunAmerica	212,188	For
John Hancock	191,443	For

Showing the 25 largest of 131 asset managers. See all 131 in the interactive database.

13. To ratify the selection of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025.

AUDIT-RELATEDCompany result: Passed

Meeting held 2025-05-20.

Combines 3 wordings of this item as funds reported it.

96% Passed · of votes cast

FOR 96%

FOR: 168,601,089AGAINST: 7,442,009

BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The ratification of the selection of KPMG LLP as BioMarin's independent registered public accounting firm for the fiscal year end”): 168,601,089 for, 7,442,009 against — passed, per its Form 8-K (Item 5.07). Of all 191,755,802 outstanding shares: 88% for, 4% against (92% of the company cast a for/against vote).

The 130 asset managers below cast 99.9% of the shares they voted on this item FOR (88,959,651 for, 35,508 against).

FOR 99.8%

FOR: 88,959,651 (99.9%)AGAINST: 35,508 (0.0%)ABSTAIN: 66,717 (0.1%)

Largest asset managers voting on “To ratify the selection of KPMG LLP as the independent registered public accounting firm for the Company for t” at BIOMARIN PHARMACEUTICAL INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	32,150,430	1,807	For
BlackRock	12,596,604	0	For
Dodge & Cox	11,525,325	0	For
Capital Group	8,669,069	0	For
Fidelity	3,339,881	0	For
State Street	3,099,809	191	For
PRIMECAP Odyssey Funds	2,994,376	0	For
Columbia Threadneedle	2,813,621	0	For
Charles Schwab	1,505,451	0	For
TIAA	843,433	0	For
Aberdeen	721,531	0	For
First Trust	664,902	0	For
Capitol Series Trust	547,000	0	For
TOUCHSTONE STRATEGIC TRUST	517,507	0	For
Dimensional	488,764	0	For
JPMorgan	455,486	0	For
American Century	447,463	0	For
Equitable	381,070	0	For
Jackson National	359,423	0	For
NEW ECONOMY FUND	289,881	0	For
Empower	246,899	0	For
AQR	236,403	0	For
Goldman Sachs	218,905	0	For
AIG/SunAmerica	212,188	0	For
John Hancock	191,443	0	For

Showing the 25 largest of 130 asset managers. See all 130 in the interactive database.

14. Amend Omnibus Stock Plan

COMPENSATIONCompany result: Passed

Meeting held 2025-05-20.

95% Passed · of votes cast

FOR 95%

FOR: 157,280,864AGAINST: 7,747,768

The 4 asset managers below cast 100% of the shares they voted on this item FOR (287,367 for, 0 against).

FOR 100%

FOR: 287,367 (100.0%)

Largest asset managers voting on “Amend Omnibus Stock Plan” at BIOMARIN PHARMACEUTICAL INC., 2024-2025
Asset manager	For	Vote
Empower	205,351	For
Erste Asset Management GmbH	56,068	For
AGF Investments Trust	22,458	For
GuideStone	3,490	For

15. To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement

SECTION 14A SAY-ON-PAY VOTESCompany result: Passed

Meeting held 2024-05-21 (outside the 2024-2025 season's 1 July to 30 June window; reported in this season's filings).

Combines 2 wordings of this item as funds reported it.

93% Passed · of votes cast

FOR 93%7%

FOR: 141,887,490AGAINST: 10,757,670

BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Proposal 3: Advisory Vote on the Compensation of Named Executive Officers The advisory (non-binding) vote to approve the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement, received ”): 141,887,490 for, 10,757,670 against — passed, per its Form 8-K (Item 5.07). Of all 191,755,802 outstanding shares: 74% for, 6% against (80% of the company cast a for/against vote).

The 3 asset managers below cast 53.6% of the shares they voted on this item FOR (525 for, 455 against).

FOR 53.6%AGAINST 46.4%

FOR: 525 (53.6%)AGAINST: 455 (46.4%)

Largest asset managers voting on “To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in t” at BIOMARIN PHARMACEUTICAL INC., 2024-2025
Asset manager	For	Against	Vote
VAUGHAN DAVID INVESTMENTS LLC/IL	525	0	For
COLDSTREAM CAPITAL MANAGEMENT INC	0	455	Against
Echo45 Advisors LLC	0	0	--

16. Ratify Appointment of Independent Auditors

AUDIT-RELATEDCompany result: Passed

Meeting held 2025-05-20.

96% Passed · of votes cast

FOR 96%

FOR: 168,601,089AGAINST: 7,442,009

The 2 asset managers below cast 4% of the shares they voted on this item FOR (1,350 for, 30,169 against).

AGAINST 96%

FOR: 1,350 (4.3%)AGAINST: 30,169 (95.7%)

Largest asset managers voting on “Ratify Appointment of Independent Auditors” at BIOMARIN PHARMACEUTICAL INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Cardano Risk Management B.V.	0	30,169	0	0	Against
VOISARD ASSET MANAGEMENT GROUP, INC.	1,350	0	0	0	For

Largest BIOMARIN PHARMACEUTICAL INC. shareholders voting in 2024-2025

Ranked by the number of BIOMARIN PHARMACEUTICAL INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 191,755,802 shares outstanding at the time of that meeting.

Top BIOMARIN PHARMACEUTICAL INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	Vanguard	17.16%
2	Dodge & Cox	13.40%
3	BlackRock	11.23%
4	PRIMECAP MANAGEMENT CO/CA/	8.90%
5	State Street	5.70%
6	VIKING GLOBAL INVESTORS LP	5.52%
7	Capital Research Global Investors	4.77%
8	Capital Group	4.52%
9	Fidelity	2.01%
10	GEODE CAPITAL MANAGEMENT, LLC	1.75%

Reported BIOMARIN PHARMACEUTICAL INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

BIOMARIN PHARMACEUTICAL INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
The Vanguard Group	9.90%	DEF14A
BlackRock, Inc.	9.16%	13G
PRIMECAP MANAGEMENT CO/CA/	8.24%	13G
Dodge & Cox	7.30%	DEF14A
Vanguard Capital Management	5.27%	13G
Entities affiliated with Viking Global Investors LP	5.09%	DEF14A
Capital Research Global Investors	4.77%	13G
State Street	4.41%	13F
VIKING GLOBAL INVESTORS LP	4.34%	13G
Norges Bank	1.81%	13F

Percentages above are of 191,755,802 shares outstanding, as reported by BIOMARIN PHARMACEUTICAL INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BIOMARIN PHARMACEUTICAL INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At BIOMARIN PHARMACEUTICAL INC.'s shareholder meeting held 2025-05-20, in the 2024-2025 proxy season, 554 asset managers reported how they voted in their SEC Form N-PX filings, covering 7,322 separate fund positions. Their filings are grouped here into 16 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as… — the proposal passed with 94% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: BIOMARIN PHARMACEUTICAL INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission (filing date not recorded for this item).

BIOMARIN PHARMACEUTICAL INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.